

IFN product pegylated interferon (PEG-IFN) it has increased to 50%.^{1–4} Today, PEG-IFN plus ribavirin regimen is internationally recognized as a standard therapy for chronic hepatitis C virus (CHCV) infection.^{5,6} Early clinical trials of this regimen focused on specific patient populations. Subsequently, several multinational studies such as WIN-R,⁷ HALT-C,⁸ EPIC3,⁹ and REPEAT Study¹⁰ have been conducted in the general clinical setting. The results of the IDEAL Study¹¹ directly comparing PEG-IFN α 2a versus PEG-IFN α 2b have also been published. From these studies, variables predictive of SVR have been identified, including ethnicity, sex, age, and weight as demographic parameters, staging and hepatic steatosis as histological parameters, viral load, genotype, NS5A, and core mutation as virologic parameters, alanine aminotransferase (ALT) and γ -glutamyl transpeptidase (GGT) as biochemical parameters, and even the timing of viral negativity as a treatment variable.^{12–15} More recently, the SVR rate was reported to increase in association with decrease in the relapse rate with 72-week treatment in patients with delayed HCV-RNA negativity.^{15,16} However, the majority of patients participating in previous studies in western countries were aged in their 40s on average, and the influence of aging of the patient population has not been studied adequately.

We therefore examined SVR-determining factors with 48-week PEG-IFN α 2b plus RBV combination therapy in the prevailing Japanese clinical setting characterized by increasing numbers of elderly patients. We also compared SVR rate between 48-week and 72-week treatment in patients with late virological response (LVR) defined as achieving HCV-RNA negativity in the period from weeks 13 to 24 after the start of treatment so as to examine the significance of prolonged treatment.

METHODS

Patients

A MULTICENTER STUDY was conducted at 68 institutions in Tokyo and Yamanashi prefectures (PERFECT Study Group; see Appendix I) to survey the actual state of combination therapy with PEG-IFN α 2b (PegIntron; Schering Plough, Kenilworth, NJ) and RBV (Rebetol, Schering Plough) in 2008. A total of 2257 chronic hepatitis C virus (CHCV) patients seen from December 2004 who completed combination treatment by September 2007 were registered regardless of genotype, history of IFN treatment, and ALT levels. The pres-

ence of HCV in serum had to be confirmed by Cobas Amplicor HCV Monitor, version 2.0 (Roche Diagnostic, Tokyo) for registration.

Excluded from this study were pregnant or possibly pregnant and lactating women, and patients with severe heart disease, chronic kidney failure or creatinine clearance of ≤ 50 mL/min, current or history of severe psychiatric disorder, and autoimmune hepatitis.

Demographic characteristics examined included age, sex, height and weight, the presence or absence of diabetes mellitus, hypertension, heavy drinking, and history of IFN therapy and hepatic cancer. Hepatic histological data recorded were stage (F0–F4) and grade (A0–A3). Laboratory tests recorded were ALT, platelet count, albumin, and α -fetoprotein (AFP) before the start of PEG-IFN α 2b plus RBV combination therapy.


As indicated in Figure 1, of the total 2257 patients registered, patients with genotype 1 and high viral load (>100 KIU/mL: Amplicor PCR quantitation) who satisfied the following conditions were included in this study: patients who received treatment for ≤ 52 weeks (standard 48-week treatment group, $n = 1480$) in study 1, and patients with LVR who received treatment for either 36–52 weeks (48-week treatment group, $n = 223$) or 60–76 weeks (72-week treatment group, $n = 73$) in study 2.

This multicenter study was approved by IRB at each participating institution. The study protocol was carried out according to the ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from each patient.

Treatment

PEG-IFN α 2b was administered subcutaneously once weekly at a dose of 1.5 μ g/kg. Dose reduction and treatment discontinuation followed the instructions given in the package insert, i.e., the dose was reduced by half if WBC decreased to $<1500/\text{mm}^3$, neutrophils to $<750/\text{mm}^3$ or platelet count to $<80000/\text{mm}^3$, and treatment was discontinued if WBC decreased to $<1000/\text{mm}^3$, neutrophils to $<500/\text{mm}^3$ or platelet count to $<50000/\text{mm}^3$. RBV was administered in two divided doses of 600, 800, or 1000 mg/day in patients weighing <60 , 60– <80 , and ≥ 80 kg, respectively. Dose reduction and treatment discontinuation followed the package insert, i.e., dose was reduced from 600 mg/day to 400 mg/day, from 800 mg/day to 600 mg/day, or from 1000 mg/day to 600 mg/day if hemoglobin (Hb) concentration decreased to <10 g/dL, and administration was discontinued if Hb decreased to 8.5 g/dL. Duration of treatment was 48 weeks as a rule. In LVR patients who did

Figure 1 Flow-chart of study subjects. (1) 48 weeks' treatment (48-week standard therapy group): patients with genotype 1 and high viral load who received pegylated interferon α 2b (PEG-IFN α 2b) + ribavirin (RBV) for 52 weeks. Multiple logistic regression analysis was used to evaluate the response to PEG-IFN α 2b + RBV in this group (2) Late virological response (LVR) 48 weeks' treatment: patients with genotype 1 and high viral load who received PEG-IFN α 2b + RBV for 36–52 weeks (3) LVR 72 weeks' treatment: patients with genotype 1 and high viral load who received PEG-IFN α 2b + RBV for 60–76 weeks. SVR rate was compared between LVR 48 weeks' treatment group (2) and LVR 72 weeks' treatment group (3). EVR, early virologic response; HCV, hepatitis C virus.



not achieve HCV-RNA negativity by week 12, treatment could be extended for 48 weeks or longer based on individual patients' desire and investigators' judgment.

Evaluation of response to treatment

Determination of genotype and measurement of HCV-RNA levels were performed at each center. Pre-treatment HCV-RNA levels were determined by Amplicor PCR quantitation. Viral negativity was defined as HCV below detection limit (<50 IU/mL) by Amplicor qualitative analysis (Roche Molecular Systems, NJ).

SVR was defined as HCV below detection limit at 24 weeks after the end of PEG-IFN α 2b plus RBV combination therapy by Amplicor HCV qualitative analysis.

Statistical analysis

All statistical analyses were performed using SAS, version 9.13 (SAS Institute, Cary, NC). Intergroup comparison of SVR rate was performed by Fisher's exact test; that of background variables by Fisher's exact test and Mann-Whitney *U*-test. Trend of SVR rate by age was assessed by Cochran-Armitage test, and intergroup comparison after adjustment of stratification factors was conducted by Mantel-Haenszel method. Determination of factors associated with SVR was conducted by a stepwise procedure using the results of logistic univari-

ate analysis ($P < 0.2$) into logistic multivariate analysis. All tests were two-sided, with significance level set at $P < 0.05$.

RESULTS

Study 1: SVR-related factors in patients receiving standard 48-week treatment

AS INDICATED IN Table 1 and Figure 1, 1480 subjects (male, $n = 898$ [60.7%]; median age, 57 [range, 13–79] years) were eligible for analysis. SVR rate based on ITT was 44.9%. SVR rate in subjects who completed and who discontinued treatment was 56.5% ($n = 1110$) and 10.3% ($n = 370$), respectively, a statistically significant difference ($P < 0.0001$). SVR rate in male subjects (50.4%; 453/898) was significantly ($P < 0.0001$) higher than in female subjects (36.4%; 212/582). SVR rate significantly ($P < 0.0001$) decreased as age increased by 10 years in both male and female subjects (Fig. 2); the odds ratio for SVR decreasing with 10-year increase in age was 0.688 (95% CI, 0.604–0.784; $P < 0.0001$) in male subjects and 0.546 (0.449–0.663; < 0.0001) in female subjects, indicating that the influence of aging was greater in female than in male subjects. There was no bias of older versus younger age among patients who had and had not previously

Table 1 Pretreatment characteristics of chronic hepatitis C virus (CHCV) patients with HCV-1b RNA who received pegylated interferon α 2b + ribavirin standard therapy for 48 weeks

Characteristic	Value (n = 1480)
Sex (male/female)	898/582
Age (years)	57 (13-79)
History of HCC (yes/no/unknown)	8/1405/67
Previous IFN treatment (yes/no/unknown)	459/688/333
Diabetes (yes/no/unknown)	44/480/956
Hypertension (yes/no/unknown)	105/417/958
Ongoing alcohol use (yes/no/unknown)	157/456/867
Grade (A0/A1/A2/A3/unknown)	14/499/478/55/434
Stage (F0/F1/F2/F3/F4/unknown)	36/469/316/176/48/435
ALT (IU/L)	63 (8.4-910)
Platelets ($\times 10^4/\mu\text{L}$)	16.6 (4.3-47.7)
Viral load (KIU/mL)	1900 (100-5100)

Data expressed as median (range). HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; IFN, interferon.

received IFN. Whereas, multivariate logistic regression analysis revealed that older age ($<55/\geq 55$ years), degree of progression of hepatic fibrosis (F0-1/2-4), low platelet count ($\geq 16/<16 \times 10^4/\mu\text{L}$), and high viral load ($<1900/\geq 1900$ KIU/mL) are resistance factors to SVR (Table 2). In multivariate logistic regression analysis, sex was not selected.

Study 2: usefulness of prolonged treatment in LVR patients

Of the patients who completed standard 48-week treatment, 223 patients (20.0%) showed LVR (Fig. 1), and median duration of treatment was 48 weeks. Compared with patients who exhibited early virologic response (EVR) defined as HCV-RNA negative within 12 weeks after the start of treatment, those with LVR were older (median age, 58 vs 55 years; $P = 0.0043$) and had higher viral load (median, 2700 vs 1620 KIU/mL; $P < 0.0001$) and lower platelet count (median, 16.5 vs $17.3 \times 10^4/\mu\text{L}$; $P = 0.0162$). SVR rate based on treatment analysis was 56.5 in all, 79.2% in EVR and 46.2% in LVR, respectively. In multivariate logistic regression analysis of SVR-related factors in LVR patients who completed standard 48-week treatment, age (10-year groups) was selected as a significant factor.




Figure 2 Sustained virological response (SVR) rate to 48 weeks' standard treatment with pegylated interferon α 2b (PEG-IFN α 2b) + ribavirin in male and female patients stratified by age. Cochran-Armitage test was used to study the underlying trend.

Table 2 Independent factors associated with sustained virological response in genotype 1 chronic hepatitis C virus patients who received pegylated interferon α 2b + ribavirin standard therapy for 48 weeks

	Odds ratio	95% confidence interval	P-value†
Age <55/≥55 years	0.414	0.293–0.585	<0.0001
Stage 0–1/2–4	0.633	0.442–0.906	0.0124
Platelets <16/≥16 × 10 ⁴ /μL	1.876	1.305–2.696	0.0007
Viral load </≥1900 KIU/mL	0.663	0.471–0.935	0.0192

†Multiple logistic regression analysis.

Prolonged treatment was conducted in 73 LVR patients (Fig. 1), with mean duration of 72 weeks. As shown in Table 3, whereas among LVR patients there were significantly ($P = 0.0061$) more female subjects in 72-week group than 48-week group, no intergroup difference of other factors was observed. Overall, SVR rate based on treatment analysis was significantly ($P = 0.0020$) higher in 72-week treatment group than in 48-week treatment group (67.1% [49/73] vs 46.2% [103/223]; Fig. 3A).

When stratified by sex, SVR rate with 48-week and 72-week treatment was 51.4% and 68.6% ($P = 0.0809$) in male subjects and 37.3% and 65.9% ($P = 0.0039$) in female subjects, with SVR in 72-week treatment being significantly higher in female subjects and indicating that, in LVR patients, efficacy comparable to male subjects is achieved in female subjects with 72-week treatment.

In patients aged <55 years SVR rate in the 48- and 72-week treatment groups was 57.6% and 78.9% ($P = 0.1100$) in male subjects and 40.0% and 76.9%

($P = 0.0724$) in female subjects, respectively, with higher SVR rates for the 72-week treatment group (Fig. 3B). In patients aged ≥55 years this parameter was 44.6% and 53.8% ($P = 0.5619$) in male subjects and 37.1% and 60.7% ($P = 0.0425$) in female subjects, respectively, with higher SVR rates for the 72-week treatment group than for the 48-week treatment group as in the case of the younger age group (Fig. 3C).

DISCUSSION

Study 1: SVR-related factors in patients receiving standard 48-week treatment

SVR RATE WITH standard 48-week treatment in this study was 44.9%, roughly equal to the 45% reported in previous clinical trials in Japan.^{4,17–19} The present results are also similar to those of clinical trials conducted in patients aged in their mid-40s in western countries and in the general clinical setting.^{1–4} Age was

Table 3 Comparison of clinical and virological characteristics between groups receiving pegylated interferon α 2b + ribavirin therapy for 48 and 72 weeks among patients showing late virological response

	48 weeks' group (<i>n</i> = 223)	72 weeks' group (<i>n</i> = 73)
Sex (male/female)	140/83*	32/41*
Age (years)	58 (21–75)	56 (22–71)
History of HCC (yes/no/unknown)	1/221/11	0/73/0
Previous IFN treatment (yes/no/unknown)	68/113/42	29/32/12
Diabetes (yes/no/unknown)	11/71/141	1/34/38
Hypertension (yes/no/unknown)	18/62/143	6/29/38
Ongoing alcohol use (yes/no/unknown)	17/75/131	6/27/40
Grade (A0/A1/A2/A3/unknown)	2/66/82/6/67	0/21/26/4/22
Stage (F0/F1/F2/F3/F4/unknown)	7/68/45/32/5/66	2/16/20/12/2/21
ALT (IU/L)	61.5 (14–550)	52 (17–254)
Platelets (×10 ⁴ /μL)	16.5 (8.5–43.2)	16.6 (4.3–40.2)
Viral load (KIU/mL)	2700 (160–5100)	2100 (130–5000)

Data expressed as median (range). * $P = 0.006$. ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; IFN, interferon.




Figure 3 Sustained virological response (SVR) rate based on treatment analysis between groups receiving pegylated interferon α 2b (PEG-IFN α 2b) + ribavirin therapy for 48 and 72 weeks who exhibited late virological response (LVR). (A) Overall; (b) patients aged <55 years; (c) patients aged \geq 55 years. Data on age not available for 7 male patients and 1 female patient.

selected among factors for SVR with PEG-IFN plus RBV combination therapy in an aging patient population, the examination of which was the objective of this study, and SVR rate decreased stepwise with 10-year age increase. Of particular note was the greater impact of aging observed in female than male subjects.

Lower efficacy in elderly female patients infected with HCV genotype 1 has already been reported in Japan.²⁰ A low SVR rate was also observed in elderly female subjects in this study. Although female sex was considered a favorable prognostic factor in some Western studies, there is no established opinion on sex difference. Change associated with aging of the patient population in Japan is considered to account for this phenomenon observed in the present study. This may be due to decrease in compliance among elderly women; on the other hand, however, there was no difference between male and female subjects aged \geq 55 years in the rate of completion of treatment. Although the rate of dose reduction of RBV tended to be slightly higher in female subjects (data not shown), the difference was not significant. These findings suggest the influence of factors other than adherence to treatment for the low SVR rate among elderly women. One possible factor for reduced SVR rate among these individuals may be the effect of menopause. In women, insulin resistance begins to worsen after the age of 50 years,^{21,22} and this is reported more closely associated with the effect of menopause than age itself.²³

The presence of insulin resistance has been reported to lower efficacy of PEG-IFN and RBV combination therapy.²⁴⁻²⁷ Insulin resistance is also a cause of advanced fibrosis and fatty change of the liver.²⁸⁻³¹ It is possible that such changes combined with other factors associated with metabolic syndrome interact in a complex way to reduce the efficacy of this therapy.³²⁻³⁵ In fact, the incidence of non-alcoholic fatty liver disease (NAFLD) among elderly Asians was reported higher in women as compared with that in men.³⁶⁻³⁸ However, while older age, advanced fibrosis, low platelet count and high HCV load were selected as factors for reduction of SVR rate in our multivariate logistic regression analysis, sex was not selected. It is therefore necessary to examine further the confounding of these selected factors with sex. It also should be taken into consideration that, due to limitations imposed by the retrospective nature of this study, data on factors affecting the efficacy of PEG-IFN plus RBV therapy such as insulin resistance, steatosis, and core mutation are lacking. A large-scale prospective study is

required to examine the lower efficacy observed in elderly women.

Study 2: usefulness of prolonged treatment in LVR patients

EVR (viral load reduced by 2 log or undetected in week 12) has been used for determining continuation or discontinuation of treatment in western countries. Recently, however, EVR was divided into complete EVR (HCV RNA <50 IU/mL at week 12) and partial EVR (>2 log drop in HCV RNA but still detectable [>50 IU/mL]). Fried *et al.*¹⁵ and Berg *et al.*¹⁶ reported that the SVR rate was a high 68–84% in patients showing complete EVR but only 17–29% in those with partial EVR with treatment for 48 weeks. They also reported that treatment for 72 weeks was effective in patients with partial EVR. In the clinical study for health registration in Japan, the SVR rate by timing of HCV-RNA negativity at 4, 12, and 24 weeks was 100%, 71.1%, and 36.4%, respectively, and no patient with HCV-RNA negativity after 25 weeks achieved SVR.⁴ With these studies as reference, patients with LVR were defined as those who were positive (>50 IU/mL) at week 12 and became negative (<50 IU/mL) by week 24. To minimize the influence of treatment discontinuation, only patients who completed the standard duration of treatment were selected as subjects in this study. In the comparison of patient background, there was no significant intergroup difference except for a significantly greater number of female subjects in the 72-week treatment group. This finding might be related to the observation that it was already widely believed that efficacy in elderly women in Japan is low and that duration of treatment was at the discretion of individual physicians. Nevertheless, it is noteworthy that the SVR rate was significantly higher in the 72-week treatment group than in the 48-week treatment group and that a high 60% SVR rate was achieved with 72-week treatment in elderly female patients, a population in whom a relatively low SVR was observed with standard 48-week treatment.

This retrospective study had the limitation that duration of treatment was at the sole discretion of each participating physician. A prospective study is necessary to demonstrate whether 72-week treatment in elderly women with LVR is more efficacious than 48-week treatment in male patients. Although the number of younger subjects examined was rather low, it is noteworthy that an SVR rate of >75% was observed with 72-week treatment in both male and female patients. This also should be confirmed by prospective study.

CONCLUSIONS

PATIENTS WITH CHCV genotype 1 infection should be treated with PEG-IFN and ribavirin combination therapy as early as possible. Seventy-two weeks' treatment is recommended in patients with LVR, regardless of age.

REFERENCES

- 1 Fried MW, Shiffman ML, Reddy KR *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. *N Engl J Med* 2002; 347: 975–82.
- 2 Manns MP, McHutchison JG, Gordon SC *et al.* Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–65.
- 3 Hadziyannis SJ, Sette H Jr, Morgan TR *et al.* Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140: 346–55.
- 4 Iino S, Okita K, Omata M, Kumada H, Hayashi N, Tanikawa K. Clinical efficacy of PEG-Interferon α 2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load—retrospective comparison with Interferon α 2b and ribavirin combination therapy for 24 weeks. *Kantansui* 2004; 49: 1099–121.
- 5 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; 39: 1147–71.
- 6 NIH. Management of hepatitis C: 2002. *NIH Consens State Sci Statements* 2002; 19: 1–46.
- 7 Jacobson IM, Brown RS Jr, Freilich B *et al.* Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *Hepatology* 2007; 46: 971–81.
- 8 Shiffman ML, Di Bisceglie AM, Lindsay KL *et al.* Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterology* 2004; 126: 1015–23.
- 9 Poynard T, Colombo M, Bruix J *et al.* Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology* 2009; 136: 1618–28.
- 10 Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. *Eur J Gastroenterol Hepatol* 2005; 17: 899–904.
- 11 McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL)

- trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. *J Viral Hepat* 2008; 15: 475–81.
- 12 Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. *Hepatology* 2008; 49: 634–51.
 - 13 Enomoto N, Sakuma I, Asahina Y *et al.* Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996; 334: 77–81.
 - 14 Akuta N, Suzuki F, Sezaki H *et al.* Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005; 48: 372–80.
 - 15 Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. *J Hepatol* 2008; 48 (Suppl. 2): 5A.
 - 16 Berg T, von Wagner M, Nasser S *et al.* Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130: 1086–97.
 - 17 Furusyo N, Kajiwara E, Takahashi K *et al.* Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. *J Gastroenterol Hepatol* 2008; 23: 1094–104.
 - 18 Tada S, Saito H, Ebinuma H *et al.* Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. *Hepatol Res* 39: 195–9.
 - 19 Akuta N, Suzuki F, Kawamura Y *et al.* Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. *Intervirology* 2007; 50: 361–8.
 - 20 Sezaki H, Suzuki F, Kawamura Y *et al.* Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. *Dig Dis Sci* 54: 1317–24.
 - 21 Otsuki M, Kasayama S, Saito H, Mukai M, Koga M. Sex differences of age-dependent changes of insulin sensitivity in Japanese nondiabetic subjects. *Diabetes Care* 2005; 28: 2590–1.
 - 22 Tamakoshi K, Yatsuya H, Wada K *et al.* The transition to menopause reinforces adiponectin production and its contribution to improvement of insulin-resistant state. *Clin Endocrinol (Oxf)* 2007; 66: 65–71.
 - 23 Otsuki M, Kasayama S, Morita S *et al.* Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. *Menopause* 2007; 14: 404–7.
 - 24 Romero-Gómez M, Del Mar Viloria M, Andrade RJ *et al.* Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology* 2005; 128: 636–41.
 - 25 D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. *Am J Gastroenterol* 2005; 100: 1509–15.
 - 26 Lo Iacono O, Venezia G, Petta S *et al.* The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2007; 25: 1181–91.
 - 27 Chu CJ, Lee SD, Hung TH *et al.* Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis c patients receiving peginterferon Alpha-2b plus ribavirin. *Aliment Pharmacol Ther* 2009; 29: 46–54.
 - 28 Hui JM, Sud A, Farrell GC *et al.* Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology* 2003; 125: 1695–704.
 - 29 Petit JM, Bour JB, Galland-Jos C *et al.* Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. *J Hepatol* 2001; 35: 279–83.
 - 30 Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. *Hepatology* 2008; 48: 723–31.
 - 31 Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. *J Gastroenterol* 2008; 43: 811–22.
 - 32 Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. *J Hepatol* 2008; 49: 634–51.
 - 33 Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. *J Gastroenterol* 2008; 43: 509–18.
 - 34 Yaginuma R, Ikejima K, Okumura K *et al.* Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. *Hepatol Res* 2006; 35: 19–25.
 - 35 Konishi I, Horiike N, Hiasa Y *et al.* Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. *Hepatol Res* 2007; 37: 331–6.
 - 36 Weston SR, Leyden W, Murphy R *et al.* Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. *Hepatology* 2005; 41: 372–9.
 - 37 Yatsuji S, Hashimoto E, Tobar M, Tokushige K, Shiratori K. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. *Hepatol Res* 2007; 37: 1034–43.
 - 38 Zhou YJ, Li YY, Nie YQ *et al.* Prevalence of fatty liver disease and its risk factors in the population of South China. *World J Gastroenterol* 2007; 13: 6419–24.

APPENDIX I


IN ADDITION TO the study authors, the investigators in the PEG-IFN and Ribavirin, Find Evidence of Chronic Hepatitis C Therapy in Tokyo (PERFECT) Study Group included: Hiroyasu Adachi, Department of Internal Medicine, Tobu Chiki Hospital; Yoshio Aizawa, Department of Internal Medicine, The Jikei University School of Medicine, Aoto Hospital; Masatoshi Akamatsu, Department of Gastroenterology, JR Tokyo General Hospital; Masahiro Arai, Department of Gastroenterology, Toshiba General Hospital; Yasuhiro Asahina, Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital; Yoshimichi Chuuganji, Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital; Yoshiyuki Fujita, Department of Gastroenterology, St. Luke's International Hospital; Yukiya Hakozaiki, Department of Internal Medicine, Self-Defence Forces Central Hospital; Naoaki Hashimoto, Department of Gastroenterology, Tokyo Teishin Hospital; Katsuya Hattori, Department of Gastroenterology, Kohsei Chuo General Hospital; Seishu Hayashi, Division of Hepatology, Tokyo Metropolitan Komagome Hospital; Masanori Hirano, Department of Gastroenterology Tokyo Metropolitan Police Hospital; Keiichi Hirata, National Hospital Organization Disaster Medical Center; Department of Gastroenterology; Yuuichi Hirose, Department of Internal Medicine, Yamanashi Prefectural Central Hospital; Toshiya Horibe, International University of Health & Welfare Mita Hospital, Gastroenterology Center; Kazuhiko Hosoda, Department of Gastroenterology and Hepatology Yamanashi Hospital of Social Insurance; Hiroaki Igarashi, Department of Gastroenterology, Kawakita General Hospital; Yoshida Ikuma, Department of Internal Medicine, Kasai Cardiology & Neurosurgery Hospital; Tetsuya Irie, Department of Internal Medicine, Nakano General Hospital; Koji Ishii, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University School of Medicine; Takayoshi Ito, Department of Gastroenterology, Department of Medicine, Showa University School of Medicine; Naohiro Kawamura, The Third Department of Internal Medicine, Kyorin University School of Medicine; Tateo Kawase, Department of Gastroenterology, Kanto Central Hospital of the Mutual Aid Association of Public School Teachers; Hirokazu Komeichi, Department of Internal Medicine, Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine, Nippon Medical School; Sadanori Kubo, Department of Internal Medicine, Showa University Toyosu Hospital;

Naohiko Masaki, Division of Gastroenterology, International Medical Center of Japan, Toyama Hospital; Akihisa Miyazaki, Department of Gastroenterology, Juntendo University Nerima Hospital; Mitsuhiko Moriyama, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University of School of Medicine; Naoya Murashima, Department of Gastroenterology, Mishuku Hospital; Hikaru Nagahara, Department of Gastroenterology, Aoyama Hospital Tokyo Women's Medical University; Hisato Nakajima, Department of Gastroenterology and Hepatology, Jikei University School of Medicine Daisan Hospital; Ikuo Nakamura, Department of Gastroenterology, Tokyo Medical University; Ryo Nakata, Department of Gastroenterology, Japanese Red Cross Medical Center; Katsuhisa Nakatsuka, Division of Gastroenterology, Department of Internal Medicine Nippon Medical School; Yasuhiro Nishizaki, Department of Gastroenterology, Tokai University Tokyo Hospital; Osamu Noguchi, Division of Gastroenterology and Hepatology, Ome Municipal General Hospital; Toshihiko Nouchi, Department of Gastroenterology, Showa General Hospital; Yuki Ogura, Department of Medicine, Tokyo Metropolitan Fuchu Hospital; Masanaru Ozawa, Yoshikawa Hospital; Shigehiko Sainokami, Fussa Hospital; Naoya Sakamoto, Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University; Minoru Sakamoto, Department of Internal Medicine, Faculty of Medicine, University of Yamanashi; Mina Sasaki, Department of Gastroenterology, Tokyo Metropolitan Geriatric Hospital; Yoshiyuki Sato, Department of Internal Medicine, Tokyo Kosei Nenkin Hospital; Koichi Shiraishi, Division of Gastroenterology and Hepatology, Tokai University Hachioji Hospital; Satoko Suzuki, Department of Gastroenterology, Juntendo University School of Medicine; Tomohiko Suzuki, Department of Internal Medicine, Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital; Fumitaka Suzuki, Department of Hepatology, Toranomon Hospital; Kazumi Tagawa, Department of Gastroenterology, Mitsui Memorial Hospital; Ichiro Takagi, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine; Seiichirou Takahashi, Department of Internal Medicine, Fujiyoshida Municipal Medical Center; Atsushi Tanaka, Department of Medicine, Teikyo University School of Medicine; Takuma Teratani, Department of Gastroenterology, Kanto Medical Center NTT EC; Katsutoshi Tokushige, Department of Medicine and Gastroenterology, Tokyo Women's Medical University; Masahiko Tomimatsu, Department of Medicine, Tokyo

Women's Medical University Medical Center East; Shigeki Tsukada, Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center; Hiroyuki Watanabe; Department of Gastroenterology, Yamanashi Red Cross Hospital; Michiyasu Yagura, Department of Gastroenterology, National Hospital Organization, Tokyo National Hospital; Haruki Yamada, Department of Internal Medicine, Social Insurance Central General Hospital; Toshio Yamada, Department of Gastroenterology, Tokyo Rinkai Hospital; Taro Yamanaka, Depart-

ment of Gastroenterology, Itabashi Chuo Medical Center; Kiyomi Yasuda, Department of Hepatology, Kiyokawa Hospital; Yuji Yoshikawa, Department of Gastroenterology, Sanraku Hospital; Yoko Yoshioka, Department of Gastroenterology, Shiseikai-daini-hospital; Hiroshi Yotsuyanagi, Department of Infectious Diseases, Internal Medicine, Graduate School of Medicine, University of Tokyo; Mikio Zeniya, Department of Gastroenterology, Jikei University Graduate School of Medicine.

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model

Jun Itakura^{a,*}, Masayuki Kurosaki^a, Yoshie Itakura^a, Sinya Maekawa^b, Yasuhiro Asahina^a, Namiki Izumi^a, Nobuyuki Enomoto^b

^a Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan

^b First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimogatou, Chuou-shi, Yamanashi 409-3898, Japan

ARTICLE INFO

Article history:

Received 30 June 2009
Received in revised form 27 August 2009
Accepted 6 September 2009

Keywords:

Agent-based model
Virus infectious disease

ABSTRACT

We created agent-based models that visually simulate conditions of chronic viral infections using two software. The results from two models were consistent, when they have same parameters during the actual simulation. The simulation results comprise a transient phase and an equilibrium phase, and unlike the mathematical model, virus count transit smoothly to the equilibrium phase without overshooting which correlates with actual biology *in vivo* of certain viruses. We investigated the effects caused by varying all the parameters included in concept; increasing virus lifespan, uninfected cell lifespan, uninfected cell regeneration rate, virus production count from infected cells, and infection rate had positive effects to the virus count during the equilibrium period, whereas increasing the latent period, the lifespan-shortening ratio for infected cells, and the cell cycle speed had negative effects. Virus count at the start did not influence the equilibrium conditions, but it influenced the infection development rate. The space size had no intrinsic effect on the equilibrium period, but virus count maximized when the virus moving speed was twice the space size. These agent-based simulation models reproducibly provide a visual representation of the disease, and enable a simulation that encompasses parameters those are difficult to account for in a mathematical model.

© 2009 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

All viruses need hosts as a basis for their life. When a virus enters the host body, it invades cells and uses both its own enzymes and those of the host cells to replicate. Host cells infected by viruses launch a self-defense system known as the innate immune system (See and Wark, 2008; Nanche, 2009), which inhibits viral replication and uses the human leukocyte antigen system and cytokines to elicit an immune response. Immune cells that have received signals from host cells activate other immune cells, neutralize viruses in the serum by means of antibodies, and prevent the virus from replicating and proliferating by destroying or curing host cells. Viral infection is a disorder based on the interactions between viruses and cells.

The power relationship between these agents changes along with the progression of the disease. In the very early stages of infection, as the host defense mechanisms are immature, the virus has the ability to overwhelm the host cells, actively replicate, and proliferate. Subsequently, as the capacity of the immune system improves, the speed of viral proliferation drops and the virus count reaches a peak. Infected host cells begin to be disrupted by the immune system or virus particles, and symptoms appear as a result. If the immune system is stronger than the virus, then the viral counts decline, and, in transient viral disorders, the virus is finally eliminated and the host recovers. In chronic viral disorders, however, the power relationship between the virus and host cells reaches equilibrium, and a long-term power balance is maintained with the virus count reaching a plateau.

Mathematical models have been proposed to study the dynamics of such viral disorders, and are regarded as being of value in understanding this phenomenon (Ho et al., 1995; Nowak et al., 1996; Neumann et al., 1998). However, these models are difficult to understand for clinicians, and their applicability is somewhat limited in everyday practice. In clinical research, measurements of viral dynamics in patients for short duration have been made for human

Abbreviations: HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus.

* Corresponding author. Tel.: +81 422 32 3111; fax: +81 422 32 9551.
E-mail address: jitakura@musashino.jrc.or.jp (J. Itakura).




Fig. 1. Simulation design and an example of simulation results. (a) Model concept. Viruses, uninfected cells, and infected cells were treated as agents, and parameters were set for each of these and for interactions between agents (underlined). (b) Flowchart of the program. After preparing the simulation, we entered the interaction cycle, in which virus steps (such as movement) and cell steps were repeated. One cycle was counted as 1 tic, and the simulation concluded after 1000 tics. (c and d) Simulation screen using (c) StarLogo and (d) RePast. Yellow circles are viruses, green squares are uninfected cells, and orange and red indicate infected cells, with orange indicating the latent period. In StarLogo, all the agents are shown on the same screen, but in RePast, viruses and cells are shown in separate windows. (e) Example of a simulation chart in StarLogo. After the start of simulation the virus count and infected cell count increase while the uninfected cell count decreases, with equilibrium state reached after a certain number of tics.




Fig. 2. Comparison of simulation results in (a) StarLogo and (b) RePast. The results were consistent when the parameters were made consistent. (Virus count [average \pm SD]: StarLogo 1458.03 ± 173.1 , RePast 1462.71 ± 178.8 , $p=0.94$. Uninfected cell count: 364.24 ± 30.4 , 368.11 ± 33.4 , $p=0.83$. Infected cell count: 105.73 ± 13.0 , 107.74 ± 13.0 , $p=0.24$. Unpaired Student's *t*-test.) Parameter values were set as follows: initial virus count, 100; uninfected cell count, 880; infected cell count, 0; virus speed of movement, 5 grids/tic; infection rate, 10%; uninfected cell regeneration rate, 1%; latent period, 3 tics; and virus reproduction rate, 5/cells/tic. The following parameter settings were taken from actual measurements: virus lifespan, 4.5 tics; uninfected cell lifespan, 49.8 tics; and infected cell lifespan, 6.7 tics.

immunodeficiency virus (HIV) (Ho et al., 1995), hepatitis B virus (HBV) (Nowak et al., 1996) and hepatitis C virus (HCV) (Neumann et al., 1998), and research is also underway on a range of models based on animal experiments and cell culture systems. As chronic viral disorders persist over long periods of time complete follow-up of viral dynamics is difficult. Furthermore, limitations of items that can be measured, such as the difficulty of measuring whole numbers of host cells, make it extremely difficult to investigate their consistency in mathematical models.

The recent ascend of dynamic-models owes much to advances in computers. Computer performance has improved markedly in recent years, not only in terms of their calculating capacity but also with regard to image displays, and models that offer a visual representation of viral disorders are now being reported (Gilbert and Bankes, 2002; Duca et al., 2007; Shapiro et al., 2008; Castiglione et al., 2007). One advantage of such visual models is that by providing a visual representation, they make understanding the disease status easy. Another benefit is that they enable parameters to be identified that are hidden as background noise in mathematical models. However, these models have some problems; it is difficult to prove the reproducibility of the simulation results derived from different languages or libraries, difficult to prove the validity of the model's concepts, and difficult to prove that the simulation results accurately reflect the reality. In this study, we created agent-based computer models that visually simulate the conditions of chronic viral infections using two software. The reproducibility of two agent-based computer models and the differences between agent-based models and the mathematical model were analyzed.

This agent-based model enabled us to investigate how each parameter included in the concept affects the conditions of chronic viral infections.

2. Methods

2.1. Selection of Software

In this study, we used two different types of softwares: StarLogo version 2.0 (<http://education.mit.edu/starlogo/>) supplied by MIT Media Laboratory and Recursive Porous Agent Simulation Toolkit (RePast-3.0, <http://repast.sourceforge.net/>) supplied by the Argonne National Laboratory. StarLogo uses Logo, one of the simplest programming languages, and has a fixed graphical user interface. RePast is a library that uses Java, another programming language, which also has a fixed graphical user interface.

Logo is an assembly language, and StarLogo carries out processing sequentially. Java is an object-oriented language, and RePast has a faster processing speed than StarLogo. In addition, StarLogo has a number of stipulations to simplify simulations, such as parameters can only be set up to five decimal places and the simulation space is also fixed as 51×51 square grids. RePast, on the other hand, has fewer such restrictions. Thus, it offers a higher degree of freedom in program settings than StarLogo. Taking simulation space as an example, in spite of the restrictions imposed by the underlying operating system's image display system, any number of grids can be set and a hexagonal grid could also be chosen rather than a square one. However, users must stipulate and set all parameters themselves. This means that they must first declare the shape of the grid and the number of grids they will use to fill the simulation space. Java is also more difficult to learn than Logo, and debugging and correcting the program is also more difficult. Thus, it is difficult to judge whether or not the results agree with the planned simulation.

In effect, these two different types of softwares are polar opposites. It is simple to start a simulation in StarLogo, but producing results takes time and it is difficult to carry out more complex simulations. In RePast it is difficult to compose the program and judge whether or not the planned study has actually been achieved, but the

simulation itself takes only a short time to complete and there are lesser restrictions in the construction of a simulation model.

2.2. Concept for Modeling

We applied the basic virus–host interaction mathematical model to the agent-based simulation system with slight modifications. The mathematical model was used to describe the dynamics of HIV (Ho et al., 1995), HBV (Nowak et al., 1996), and HCV (Neumann et al., 1998) and the only agents involved were host cells and viruses, without the inclusion of immune cells. The effects of the immune system are expressed by varying parameters such as lifespan of host cells and viruses.

Fig. 1a illustrates the study concept. Viruses have the ability to infect healthy host cells (uninfected cells) and the infected cells produce new viruses. Both cells and viruses have definite lifespans, and the lifespan of infected cells is usually shorter than that of uninfected cells. Uninfected cells automatically regenerate within the space, whereas infected cells only arise due to infection of uninfected cells. Viruses also lack the ability to regenerate themselves and are only produced from infected cells.

2.3. Parameter Settings

In the present study, as the StarLogo settings are circumscribed, we limited the simulation space to 51×51 square grids. However, we made an exception here while investigating the effects of size of space on the simulation results. The numbers of viruses, uninfected cells, and infected cells could only be set before the start of the simulation. As described in the later, our simulation ran in cycles, with 1 cycle defined as 1 tic.

In mathematical simulation models, the death rate is required as a parameter. However, in our program we set lifespans for viruses and uninfected cells. These lifespans were not uniform, but were set to have a deviation of about 10%. The lifespan of cells was shortened by infection with ratio decided beforehand.

The infection ratio was meaningful only when an infected cell and a virus coincidentally occupied the same grid, and this was used to calculate the probability of the infection occurring in that situation. The virus production rate was set as the number of viruses produced by an infected cell during 1 tic. Infected cells could be set as a parameter indicating the latent period between the time of virus infection and the time of virus replication.

In order to emulate the tissue repair capacity, we set uninfected cell regeneration rate such that grids without any cells had a specified probability of producing uninfected cells on top of themselves. As a result, the more the cell count declined within a space the more regenerated uninfected cells were produced, whereas the number of regenerated cells declined as cell count increased.

The number of grids through which a virus could move in 1 tic was set as the speed of movement, and the direction of movement was set within a range of 90° toward the top of the simulation space. The program used a circulatory method of movement; when a virus arrived at the top of the space, it was translocated to the bottom, and moved again toward the top. Cells were fixed on the grid.

2.4. Simulation Flowchart

Fig. 1b shows a flowchart of the program. First, the simulation space was produced, after which each parameter was defined and the initial settings were made. Next the agents – viruses and uninfected and infected cells – were produced. The simulation cycle was as follows. Viruses moved to a new grid, and if an uninfected cell was present, this was infected with a probability based on the infection rate. The lifespan of the virus decreased, and viruses that had completed their lifespan and those that had caused an infection were removed from the space. Infected cells produced new viruses, the lifespans of both uninfected and infected cells decreased. Then, cells that had completed their lifespan were eliminated and a new cycle began. The program was set such that the simulation ended after this cycle had repeated 1000 times. This meant that one simulation was complete after 1000 tics.

2.5. Data Collection

The RePast model was programmed such that data for each tic was saved automatically as a text file at the end of the simulation. This text file could be opened by a database software. The StarLogo model was programmed to stop the simulation and collect data after every 50 tics.

2.6. Mathematical Model

In order to compare the results of this agent-based simulation, we used a viral infection mathematical model, which we improved as follows.

$$\frac{dT}{dt} = s[2601 - (T + I)] - dT - bVT \quad (1)$$

$$\frac{dI}{dt} = bVT - dI \quad (2)$$




Fig. 3. Comparison of results of agent-based simulation and mathematical simulation. Both sets of results were consistent for the equilibrium phase, but differed in the shift in transition phase. Black line: mathematical model; grey line: results of simulation in RePast. Parameter values were set as follows: initial virus count, 100; uninfected cell count, 880; infected cell count, 0; virus speed of movement, 5 grids/tic; infection rate, 10%; uninfected cell regeneration rate, 1%; latent period, 3 tics; virus reproduction rate, 5/cells/tic; virus lifespan, 10 tics; uninfected cell lifespan, 50 tics; and cell lifespan-shortening ratio as a result of infection, 69%.

$$\frac{dV}{dt} = pI - cV \quad (3)$$

where, T is the uninfected cell count, I is the infected cell count, and V is the virus count. Uninfected cells are supplied to the space with a probability $s[2601 - (T + I)]$, as the number of grids in this agent-based simulation model was 2601 (51×51). The death rate of uninfected cells is d , the death rate of infected cells is δ , and the death rate of viruses is c . The infection rate is indicated by β . Viruses are released from infected cells at a probability p .

2.7. Statistical Analysis

Statistical analyses were performed by statistical tests using the program StatView 5.0 (SAS Institute Inc.). All tests of significance were two-tailed, with p values of <0.05 considered to be significant.

3. Results

3.1. Reproducibility of Chronic Viral Infection Disease Models Using Agent-based Simulation Methods

We constructed the chronic viral infection model with StarLogo library. Fig. 1c shows the simulation screen, and Fig. 1e shows one sample result. Immediately after the start of the simulation, the virus count temporarily dropped in accordance with the onset of an infection. Subsequently, the virus count started to increase with an increase in the infected cells and a decrease in the uninfected cells. After a certain number of tics (around 300 in this example), although the virus count, infected cell count, and uninfected cell count had some fluctuation, an equilibrium state was reached. We use the following descriptive terms in this paper: the transient phase is the period during which virus growth peaks, and the equilibrium phase is the period during which an equilibrium state is




Fig. 4. Effects of changes in viral parameters. (a) The higher the initial virus count, the greater is the increase in the rate of formation of chronic infection, but (b) there was no effect on the conditions in the equilibrium phase. (c) Extending the virus lifespan increased the virus count. (d) Increasing the speed of virus movement to 100 grids/tic increased the virus count, but increasing it to 500 grids/tic had the opposite effect, with a slight declining trend. (a) Black bars: number of infections produced; (b–d) black circles: virus count; line: virus count approximation curve; white bars: uninfected cell count; black bars: infected cell count.

established. When the simulation was performed multiple times, the features described above were maintained, and the average values for virus, infected cell, and uninfected cell counts during the equilibrium state were all consistent.

Fig. 1d shows the simulation screen of the RePast. When we attempted setting all the initial parameters to the same values as those in the StarLogo, the results were not consistent. When we recalculated the parameters from the simulation results, in RePast, the parameters were largely maintained at the levels of the settings, but in StarLogo, the lifespans of both cell types became shorter than the settings while the simulation was in progress. We made the results of both simulations consistent by using the same parameters during the actual simulation (Fig. 2a and b).

3.2. Comparison Between Agent-based Simulation Models and Mathematical Simulation Model

We investigated whether the results of a chronic viral infection disease model produced by RePast would be consistent with the results of a mathematical model. For the mathematical model, we carried out an approximate integration using a four-dimensional Runge–Kutta method to ensure that the uninfected cell count and infected cell count would be in the same class. Parameters were always fixed as constant between simulations. The simulation results were consistent for the equilibrium

phase, but transitions in virus count during the transient phase varied, with a shift to equilibrium state following two overshoots in the mathematical model, but a monotonic increase following a logistic curve in the agent-based model (Fig. 3). In the mathematical model, when the equilibrium condition was calculated with $dI/dt = dI/dt = dV/dt = 0$, the equilibrium-phase virus count, uninfected cell count, and infected cell count were very similar to those of the agent-based model (virus count: mathematical model 371.8/space, agent-based model 371.1 ± 32.4 /space [average \pm SD]; uninfected cell count: mathematical model 1605/space, agent-based model 1454 ± 194 /space; infected cell count: mathematical model 115.9/space, agent-based model 108.3 ± 14.2 /space).

3.3. Usability of the Models; Effect of Changing Parameters

We investigated the changes in the equilibrium phase brought about by changing each parameter. All the investigations below were carried out by using RePast, and we used the average values from ten simulations.

3.4. Viral Parameters

The lower the virus counts at the beginning of the simulation, the lower the probability of a chronic infection (Fig. 4a). However, the initial virus count did not have any effect on the equilibrium




Fig. 5. Effects of changes in cell parameters. (a) Extending the uninfected cell lifespan and (b) increasing the uninfected cell regeneration rate increased the virus count. (c) Raising the lifespan-shortening ratio as a result of infection shortened the lifespan of infected cells, thereby decreasing the virus count. (d) Extending the latent period shortened the period of virus production from infected cells, thereby decreasing the virus count. (e) Increasing the virus production count resulted in a linear increase in equilibrium-phase virus count. Black circles: virus count; line: virus count approximation curve; white bars: uninfected cell count; black bars: infected cell count.

phase itself (Fig. 4b). Extending the lifespan of viruses resulted in a linear increase in equilibrium-phase virus count (Fig. 4c). Although the infected cell count increased, the rate of increase gradually declined. Changing the speed of viral movement resulted in the equilibrium-phase virus count to eventually decline after 100 grids/tic was reached, allowing movement over an area twice the size of the simulation space (Fig. 4d).

3.5. Uninfected Cell Parameters

Extending the lifespan of uninfected cells led to an increased virus count during the equilibrium phase (Fig. 5a). Increasing the uninfected cell regeneration rate also contributed to increased equilibrium-phase virus count (Fig. 5b). In both the cases, the

increases in virus count and infected cell count were not linear, but showed a tendency for the rate of increase to decline gradually.

3.6. Infected Cell Parameters

We carried out an investigation of the effects of variation in the lifespan-shortening ratio on the virus count on the assumption that cell lifespan is shortened by infection. When this ratio was increased, the virus count decreased (Fig. 5c). An extended latent period was also related to a decreased virus count (Fig. 5d). However, the virus production from infected cells led to a linear increase in the virus count (Fig. 5e).




Fig. 6. (a) Increasing the infection rate increased the virus count in equilibrium periods, but the virus count did not change at infection rates of 30% or more. (b) The size of the simulation space increased not only virus count but also the cell count; however, (c) when virus and cell counts were divided by the total number of grids in the space, they were constant for all space sizes. (d) Changing the lifespan and regeneration rate of uninfected cells in opposite directions at the same time makes it possible to change only the cell cycle speed without altering the uninfected cell count. (e) When the cell cycle speed was reduced, the virus count increased toward the right of the graph. This may be because the effect of extending the lifespan of cells exceeds that of reducing their regeneration rate. (a–c and e) Black circles: virus count; line: virus count approximation curve; white bars: uninfected cell count; black bars: infected cell count.

3.7. Infection Rate and Space Size

Increasing the infection rate caused an increase in the virus count, but the change was minimal at an infection rate of 30% or more. The same results were seen for infected cell count, but a decrease in uninfected cell count resulted in a tendency for the infection rate to decrease by up to 60% (Fig. 6a).

The larger the space, higher the increase in both virus and cell counts (Fig. 6b). This increase was proportional to space size, how-

ever, when virus and cell counts were divided by the total number of grids in the space they were all constant (Fig. 6c).

3.8. Cell Cycle Speeds

Running a simulation with the initial virus count set to zero enables only the equilibrium condition for uninfected cells to be simulated. Changing the lifespan and regeneration rate of uninfected cells in opposite directions at the same time makes it possible

to change the cell cycle speed without altering the uninfected cell count (Fig. 6d). We used this technique to investigate how changing the cell cycle speed affected the equilibrium phase. Fig. 6e shows the results. Cell lifespan increases while the cell cycle speed declines. The equilibrium virus count increased in accordance with slower cell cycle speeds.

4. Discussion

In this study, we investigated the models using two agent-based simulation methods to program a simple virus–host chronic infection model. The same model written in two different programming language systems displayed the same results. The transient phase was unlike that seen in a mathematical simulation with no overshoot in virus count, but rather a smooth transition to the equilibrium phase. The virus count at the start of the simulation only had effect on the rate of infection development. Increases in virus lifespan, uninfected cell lifespan, uninfected cell regeneration rate, virus production count from infected cells, and infection rate all led to increased equilibrium-phase virus count. Rises in the infected cell lifespan-shortening ratio, latent period, and cell cycle speed decreased the equilibrium-phase virus count. The size of the space itself had no innate effect on the equilibrium phase, but a speed of movement of the virus that was twice the size of the space produced the maximum virus count.

Reproducibility is the basis for all scientific study, but there are many problems to prove it in computer simulations, such as programming bugs. As agent-based simulation deals with numerous agents individually, it requires vast amounts of calculations. Accumulation of very small change of values leads to large differences of results. In this study, we investigated two programs based on two programming languages to confirm the reproducibility of our simulation results in different programming languages. The results of two simulations were consistent, but in StarLogo, the lifespan parameters had a tendency to be lower than when they were set while simulations were actually in progress. This may be because the number of digits used in calculations was different between the two programs. RePast performs calculations to at least eight decimal places. In StarLogo, the library settings only enable settings to be made up to five decimal places. It is probable that these small differences accumulate during repeated calculations and are reflected in the simulation. Ultimately, we confirmed that the differences in results obtained by using different libraries and programming languages were not innate and by making the parameters consistent during simulation, consistent results were obtained.

Mathematical models using formulae for HIV therapy was published in 1994, the method has since been applied to HBV and HCV (Ho et al., 1995; Nowak et al., 1996; Neumann et al., 1998), and they were thought to be good reflections of the reality. In the mathematical model, viruses and cells are conceived as individuals in the concept itself, but both of them are perceived *en masse* when calculations are performed. However a feature of the agent-based simulation is that it deals with individual viruses and cells as separate agents. By moving each agent individually, it probes the factors influencing overall shifts from the micro viewpoint. When the space is viewed as a whole, it is possible to watch on the screen the collective movement of groups of agents. Recently, models that provide a visual representation of Epstein–Barr virus and HIV infection have been reported, both of which are useful for an instinctive and intuitive understanding (Duca et al., 2007; Shapiro et al., 2008; Castiglione et al., 2007).

In agent-based simulation model, virus count transit smoothly to the equilibrium phase. On the other hand, virus counts overshoot during transient phase in mathematical model. We think this difference is derived from technicality of different model-

ing. The difference in concepts between mathematical models and agent-based models is the space. The mathematical model has no space in concept, but agents move across the space in the agent-based model. In agent-based models, the densities of virus and cells change overtime especially in the transition phase because of the limited space. These changes of the densities of virus and cells lead to the dynamic change of the encounter rate of viruses and cells. The mathematical model does not make such concept of the density; the encounter rate is constant. This may be the reason for the difference between two models in the transition phase. Since no overshoot of virus counts in transient phase had been reported from *in vivo* studies of hepatitis C virus and simian immunodeficiency virus (Dahari et al., 2005; Nowak et al., 1997), agent-based model correlates with actual biology *in vivo* at least for these viruses. The increase of initial virus count at the start of simulation correlates with higher encounter rate of viruses and cells which make the linear increasing of infection forming rate. Mathematical model can only express the infection formation rate as “infected or not”.

The importance of viral passing speed in the agent-based model is also explained by the “space”. Although the virus actually moves through the blood stream in our body and virus could not decide their moving speeds by themselves, there is most appropriate speed for virus to meet the cells on the simulation space by the highest probability. The effect of cell cycle speed should be mentioned by another affection of the space. A fast cell cycle speed means that the lifespan of uninfected cells is short. Then fast cell cycle speed leads to the short lifespan of infected cells. A higher regeneration rate for uninfected cells results in a higher rate of infection among uninfected cells by viruses, but in situations where viruses and cells are dispersed around the space this is ineffective in increasing the infection rate, as the latter depends on the probability that they will encounter one another. As a result, the infected cell count decreases during the equilibrium phase, as does the virus count.

In this study, we confirmed the reproducibility and usability of agent-based models in expressing the interaction between viruses and cells. A feature of this simulation system is that it uses the concept of space as actual space, which means that the existence of the space becomes an additional controlling factor on the simulation results. This is a concept that is absent from mathematical models. The reality is that we have a spatial existence, and an advantage of the agent-based simulation system is the fact that it accounts for the space. Another feature of the simulation system is that it enables the condition to be perceived in visual terms, making it easy to understand. However it may be affected by computer performance and by the limitations of programming languages or the program itself, this system may offer a powerful tool for the future analysis of real virus–host interaction disease.

Conflict of interest

No conflicts of interest exist for all authors.

References

- Castiglione, F., Pappalardo, F., Bernaschi, M., Motta, S., 2007. Optimization of HAART with genetic algorithms and agent-based models of HIV infection. *Bioinformatics* 23, 3350–3355, doi:10.1093/bioinformatics/btm408.
- Dahari, H., Major, M., Zhang, X., Mihalik, K., Rice, C.M., Perelson, A.S., Feinstone, S.M., Neumann, A.U., 2005. Mathematical modeling of primary hepatitis c infection: noncytolytic clearance and early blockage of virion production. *Gastroenterology* 128, 1056–1066, doi:10.1053/j.gastro.2005.01.049.
- Duca, K.A., Shapiro, M., Delgado-Eckert, E., Hadinoto, V., Jarrar, A.S., Laubenbacher, R., Lee, K., Luzuriaga, K., Polys, N.F., Thorley-Lawson, D.A., 2007. A virtual look at Epstein–Barr virus infection: biological interpretations. *PLoS Pathog.* 3, 1388–1400, doi:10.1371/journal.ppat.0030137.
- Gilbert, N., Bankes, S., 2002. Platforms and methods for agent-based modelling. *Proc. Natl. Acad. Sci. U.S.A.* 99 (Suppl. 3), 7197–7198.

- Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., Markowitz, M., 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* 373, 123–126, doi:10.1038/373123a0.
- Naniche, D., 2009. Human immunology of measles virus infection. *Curr. Top. Microbiol. Immunol.* 330, 151–171.
- Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S., 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 282, 103–107, doi:10.1126/science.282.5386.103.
- Nowak, M.A., Bonhoeffer, S., Hill, A.M., Boehme, R., Thomas, H.C., McDade, H., 1996. Viral dynamics in hepatitis B virus infection. *Proc. Natl. Acad. Sci. U.S.A.* 93, 4398–4402.
- Nowak, M.A., Lloyd, A.L., Vasquez, G.M., Wiltrout, T.A., Wahl, L.M., Biscoberger, N., Williams, J., Kinter, A., Fauci, A.S., Hirsch, V.M., Lifson, J.D., 1997. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. *J. Virol.* 71, 7518–7525.
- Shapiro, M., Duca, K.A., Lee, K., Delgado-Eckert, E., Hawkins, J., Jarrah, A.S., Laubacher, R., Polys, N.F., Hadinoto, V., Thorley-Lawson, D.A., 2008. A virtual look at Epstein-Barr virus infection: simulation mechanism. *J. Theor. Biol.* 252, 633–648, doi:10.1016/j.jtbi.2008.01.032.
- See, H., Wark, P., 2008. Innate immune response to viral infection of the lungs. *Paediatr. Respir. Rev.* 9, 243–250, doi:10.1016/j.prrv.2008.04.001.

Clinical significance of immunoglobulin G4-associated autoimmune hepatitis

Takeji Umemura · Yoh Zen · Hideaki Hamano · Satoru Joshita ·
Tetsuya Ichijo · Kaname Yoshizawa · Kendo Kiyosawa · Masao Ota ·
Shigeyuki Kawa · Yasuni Nakanuma · Eiji Tanaka

Received: 25 June 2010 / Accepted: 25 August 2010 / Published online: 23 September 2010
© Springer 2010

Abstract

Background Immunoglobulin (Ig) G4-associated autoimmune hepatitis (AIH) is a recently identified and possibly new disease entity. However, the epidemiology and clinical features of IgG4-associated AIH remain uncertain. The aim of this study was to determine the prevalence and the clinical, serological, and histological characteristics of IgG4-associated AIH.

T. Umemura (✉) · H. Hamano · S. Joshita · T. Ichijo ·
K. Yoshizawa · K. Kiyosawa · E. Tanaka
Division of Hepatology and Gastroenterology,
Department of Medicine,
Shinshu University School of Medicine,
3-1-1 Asahi, Matsumoto 390-8621, Japan
e-mail: tumemura@shinshu-u.ac.jp

M. Ota
Department of Legal Medicine,
Shinshu University School of Medicine, Matsumoto, Japan

S. Kawa
Center for Health, Safety, and Environmental Management,
Shinshu University, Matsumoto, Japan

Y. Zen
Division of Pathology, Kanazawa University Hospital,
Kanazawa, Japan

Y. Nakanuma
Department of Human Pathology, Kanazawa University
Graduate School of Medicine, Kanazawa, Japan

Present Address:

Y. Zen
Institute of Liver Studies, King's College Hospital, London, UK

Present Address:

K. Kiyosawa
Department of Internal Medicine,
Nagano Red Cross Hospital, Nagano, Japan

Methods We examined the clinical features, serum IgG4 concentration, liver biopsy histology, and IgG4-bearing plasma cell infiltration of 60 patients with type 1 AIH and 22 patients with autoimmune pancreatitis.

Results High serum IgG4 concentration (≥ 135 mg/dL) and IgG4-bearing plasma cell infiltration in the liver (≥ 10 /high-power fields [HPFs]) were found in 2 of the 60 (3.3%) patients with type 1 AIH. These patients had high serum levels of IgE, giant cell change, and rosette formation in the liver. Although corticosteroid therapy reduced the serum IgG4 concentration and normalized liver enzymes and histology, one patient developed IgG4-related sclerosing cholangitis after 5 years of follow-up.

Conclusions Because IgG4-associated AIH was found in over 3% of Japanese patients with type 1 AIH in our cohort, further studies are needed on this possible new disease entity and its impact on the diagnostic guidelines of AIH.

Keywords Autoimmune hepatitis · Autoimmune pancreatitis · IgG4 · Histology · Sclerosing cholangitis

Introduction

Autoimmune hepatitis (AIH) is an organ-specific autoimmune disease characterized by chronic inflammation of the liver, elevated transaminase levels, hypergammaglobulinemia, serum autoantibodies, histological evidence of interface hepatitis, and a favorable response to immunosuppressive treatment [1–3]. Type 1 AIH is the major form of AIH in Japanese and Caucasoid adults, and can be distinguished by the presence of circulating anti-nuclear antibodies (ANA) and/or anti-smooth muscle antibodies (SMA). The diagnosis of type 1 AIH is based on the